All In Biotech

Drug Trial Radar · NCT05560646

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 354 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

354

Actual

Start

Oct 25, 2022

Primary completion

May 28, 2025

Study completion May 28, 2025

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Sep 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.

Conditions

  • Endometriosis

Interventions

  • OG-6219Drug

    OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.

  • PlaceboDrug

    Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
  2. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days
  3. Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment DiscontinuationTime frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days

Locations

86 sites in 11 countries. Site status is shown where the registry gives one.

  • Central Research Associates LLC dba Flourish Research

    Birmingham, Alabama

  • UAB Center for Women's Reproductive Health

    Birmingham, Alabama

  • Olympia Clinical Trials

    Los Angeles, California

  • Yale Fertility Center

    Orange, Connecticut

  • Physician Care Clinical Research, LLC

    Sarasota, Florida

  • University of South Florida

    Tampa, Florida

  • MediSense Inc

    Atlanta, Georgia

  • Paramount Research Solutions

    College Park, Georgia

  • Infinite Clinical Trials

    Morrow, Georgia

  • The Advanced Gynecologic Surgery Institute

    Park Ridge, Illinois

  • Ochsner Health Center - Baptist McFarland Medical Plaza

    New Orleans, Louisiana

  • Omni Fertility and Laser Institute

    Shreveport, Louisiana

  • John Hopkins University

    Baltimore, Maryland

  • Bosque Women's Care

    Albuquerque, New Mexico

  • University of Cincinnati

    Cincinnati, Ohio

  • Centricity Research Dublin

    Dublin, Ohio

  • Penn State Health Women's Health Clinic

    Hershey, Pennsylvania

  • Clinical Research of Philadelphia, LLC

    Philadelphia, Pennsylvania

  • Palmetto Clinical Research

    Summerville, South Carolina

  • Chattanooga Medical Research, LLC

    Chattanooga, Tennessee

  • Cedar Health Research, LLC

    Euless, Texas

  • The Women's Hospital of Texas

    Houston, Texas

  • Clinical Trial Network LLC

    Houston, Texas

  • Northeast Clinical Research of San Antonio

    San Antonio, Texas

  • Wasatch Clinical Research

    Salt Lake City, Utah

  • Tidewater Clinical Research

    Norfolk, Virginia

  • Seattle Women's: Health, Research, Gynecology

    Seattle, Washington

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • AZ Jan Palfijn Gent

    Ghent, Belgium

  • Universitair Ziekenhuis Ghent

    Ghent, Belgium

  • Jessa Ziekenhuis Hospital

    Hasselt, Belgium

  • CHU de Tivoli

    La Louvière, Belgium

  • Medical Center Repromed EOOD

    Pleven, Bulgaria

  • UMHAT "Sv. Georgi", EAD

    Plovdiv, Bulgaria

  • DCC " Ascendent" EAD

    Sofia, Bulgaria

  • SHATOD - Sofia District, EOOD

    Sofia, Bulgaria

  • MHAT for women's health - Nadezhda, OOD

    Sofia, Bulgaria

  • DCC "Alexandrovska", EOOD

    Sofia, Bulgaria

  • Medical Center Hera EOOD

    Sofia, Bulgaria

  • Group practice for specialized medical care in the field of obstetrics and gynecology - Gin Art OOD

    Sofia, Bulgaria

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.